

<sup>1</sup> Department of Clinical Neurophysiology, Neurology, Aarhus University Hospital, Aarhus and Danish Epilepsy Centre, Dianalund, Denmark

<sup>2</sup> Department of Neurology, Duke University Medical Center, Durham, North Carolina, USA and Neurodiagnostic Center, Veterans Affairs Medical Center, Durham, North Carolina, USA

<sup>3</sup> Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine, Kyoto, Japan

<sup>4</sup> Neurology Unit, Department of Medicine, Sultan Qaboos University Hospital, Sultan Qaboos University, Sultanate of Oman

<sup>5</sup> UCL NIHR BRC Great Ormond Street Institute of Child Health, Great Ormond Street Hospital for Children, London, member of ERN EpiCARE, and Young Epilepsy Lingfield, UK

<sup>6</sup> Department of Paediatric Neurology, Red Cross War Memorial Children's Hospital, Neuroscience Institute, University of Cape Town, South Africa

<sup>7</sup> EEG & Epilepsy Unit, University Hospital of Geneva, Medical Faculty of the University of Geneva, Switzerland

<sup>8</sup> Department of Neurology, University Medical Center, Göttingen, Germany

<sup>9</sup> Institute of Neurology, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Uruguay

<sup>10</sup> Department of Clinical Neurosciences, University of Calgary, Canada

<sup>11</sup> Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, USA

<sup>12</sup> Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University and Centre for Cognitive Neuroscience, Salzburg, Austria, Affiliated EpiCARE Partner; Neuroscience Institute, Christian Doppler University Hospital, Salzburg, Austria; Department of Public Health, Health Services Research and Health Technology Assessment, UMIT – University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria

Received March 10, 2021; Accepted April 25, 2021

\*This article also appears in volume 132, issue 9 of the International Federation of Clinical Neurophysiology's journal *Clinical Neurophysiology* published by Elsevier B.V.

# Importance of access to epilepsy monitoring units during the COVID-19 pandemic: consensus statement of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology\*

Sándor Beniczky<sup>1</sup>, Aatif Husain<sup>2</sup>, Akio Ikeda<sup>3</sup>, Haifa Alabri<sup>4</sup>, J. Helen Cross<sup>5</sup>, Jo Wilmshurst<sup>6</sup>, Margitta Seeck<sup>7</sup>, Niels Focke<sup>8</sup>, Patricia Braga<sup>9</sup>, Samuel Wiebe<sup>10</sup>, Stephan Schuele<sup>11</sup>, Eugen Trinka<sup>12</sup>

**ABSTRACT** – Restructuring of healthcare services during the COVID-19 pandemic has led to lockdown of epilepsy monitoring units (EMUs) in many hospitals. The ad-hoc taskforce of the International League Against Epilepsy (ILAE) and the International Federation of Clinical Neurophysiology (IFCN) highlights the detrimental effect of postponing video-EEG monitoring of patients with epilepsy and other paroxysmal events. The taskforce calls for action for continued functioning of EMUs during emergency situations, such as the COVID-19 pandemic. Long-term video-EEG monitoring is an essential diagnostic service. Access to video-EEG monitoring of the patients in the EMUs must be given high priority. Patients should be screened for COVID-19, before admission, according to the local regulations. Local policies for COVID-19 infection control should be adhered to during the video-EEG monitoring. In cases of differential diagnosis in which reduction of antiseizure medication is not required, home video-EEG monitoring should be considered as an alternative in selected patients.

**Key words:** COVID-19 pandemic; epilepsy monitoring units (EMUs); ILAE; IFCN; video-EEG

• **Correspondence:**  
Sándor Beniczky  
Danish Epilepsy Centre  
Clinical Neurophysiology  
Visbys Allé 5, Dianalund 4293,  
Denmark  
<sbz@filadelfia.dk>

## Background and justification

The International League Against Epilepsy (ILAE) and the International Federation of Clinical Neurophysiology (IFCN) appointed an ad-hoc taskforce to provide a rapid response to the challenges concerning video-EEG monitoring, encountered during the current pandemic, caused by the coronavirus SARS-CoV-2 disease (COVID-19). Through consensus discussions, review of the published evidence and experience of the experts representing the two societies, the ad-hoc taskforce elaborated this statement.

During the restructuring of healthcare services due to the current pandemic, many hospitals closed video-EEG monitoring facilities, referred to in this document as epilepsy monitoring units (EMUs) [1]. A European survey showed that in most centres, inpatient video-EEGs monitoring had been stopped (61.7% for adults, 36.2% for children) or was restricted (38.3% for adults, 53.2% for children) [1], with detrimental effects on patients with complex and severe epilepsy and other paroxysmal events [1], such as a lack of optimizing medical treatment and lack of evaluation for epilepsy surgery. The likelihood of triggering seizure emergencies in patients with epilepsy and neurological complications is limited. The measures used to close EMUs were adopted by healthcare providers to focus on re-allocation of resources to services, considered more important and more immediately required, and to prevent spreading the disease. Long-term video-EEG monitoring in EMUs was regarded by the healthcare providers as an elective procedure that could be postponed without significant consequences, a categorization that we challenge as incorrect for the following reasons.

Long-term video-EEG monitoring is an essential diagnostic tool for patients with complex and severe epilepsy [2, 3]. The main indications are diagnostic and presurgical evaluation [2, 3]. While video-EEG monitoring is diagnostic, it has direct implications on treatment of epileptic seizures, co-morbidities and important differential diagnoses (arrhythmia and cardiac death, psychogenic non-epileptic seizures and the risk of suicide).

### Reasoning for continuing diagnostic monitoring

Approximately one third of patients referred to specialized centres based on a suspicion of drug-resistant epilepsy do not have epilepsy [4-7]. Persistent misdiagnosis of paroxysmal events, often cardiac or psychogenic in origin, has severe consequences for them [8-10]. In patients with drug-resistant epilepsy, misclassification of the seizure types can lead to

inadequate choice of antiseizure medication [2]. Video-EEG recording of the patients' habitual clinical episodes is the diagnostic gold standard for patients with unclear paroxysmal events [2, 3].

### Reasoning for continuing presurgical evaluation

Epilepsy surgery is the evidence-based treatment for patients with drug-resistant focal epilepsy [11-13]. This requires video-EEG recording of the seizure, and in around one third of patients, invasive monitoring [2, 3]. Failure to proceed towards surgery unnecessarily exposes the patients to further seizures, injuries associated with seizures and the risk of sudden unexpected death in epilepsy (SUDEP) [14]. The appropriate and unrestricted utilization of EMUs in comprehensive epilepsy centres has been shown to reduce mortality of patients with epilepsy [15]. High-quality epilepsy care, including video-EEG monitoring, has decreased morbidity and mortality [15-17]. Hence, increasing waiting times can cause considerable problems, increasing morbidity and mortality. These patients often have worsening epilepsy and co-morbidities, and prioritizing care with restricted resources becomes more and more challenging. Some EMUs have managed to continue video-EEG monitoring during the pandemic [1]. Using measures of prevention and protection generally adopted in the hospitals, these EMUs were able to continue this important diagnostic function, without causing local outbreaks [1, 15, 18, 19]. Recommendations for neurophysiology staff with risk factors for COVID-19, and for the mental health of the staff have been proposed by the Latin American chapter of the IFCN Task Force – COVID-19 [20].

### Summary statements

The ILAE-IFCN ad-hoc taskforce issues the following statement, related to functioning of EMUs during the COVID-19 pandemic:

- 1. Long-term video-EEG monitoring is an essential diagnostic service.
- 2. Access to video-EEG monitoring of the patients in the EMUs must be given high priority.
- 3. Patients should be screened for COVID-19, before admission, according to local regulations.
- 4. Local policies for COVID-19 infection control should be adhered to during the video-EEG monitoring.
- 5. In cases of differential diagnosis, in which reduction of antiseizure medication is not required, home video-EEG monitoring should be considered as an alternative in selected patients.

## Conclusion

The ILAE-IFCN ad-hoc taskforce calls for action to ensure that healthcare providers understand the importance of providing diagnostic services for patients with epilepsy and paroxysmal events, and that EMUs continue functioning during emergency situations like the COVID-19 pandemic, while adhering to local healthcare policies. ■

### Disclaimer.

This report was written by experts selected by the International League Against Epilepsy (ILAE) and the International Federation of Clinical Neurophysiology (IFCN) and was approved for publication by the ILAE and IFCN. Opinions expressed by the authors, however, do not necessarily represent the policy or position of the ILAE and IFCN.

### Conflict of interest statement.

Sándor Beniczky reports speaker honoraria and personal fees from: Natus Neuro, Philips EGI, Epihunter, UCB Pharma, Eisai and Bial-Portela, outside this work.

Aatif Husain has received personal compensation for consulting from: UCB Pharma, Jazz Pharma, BlackThorn Therapeutics, Eisai Pharmaceuticals, Marinus Pharmaceuticals, Neurelis Pharmaceuticals, and Merck. He has also received royalties from Wolters Kluwer, Springer and Demos Publishers. Additionally, he has received stipend for editorship from American Clinical Neurophysiology Society.

Akio IKEDA belongs to Department of Epilepsy, Movement Disorders and Physiology which is the Industry-Academia Collaboration Courses, supported by Eisai Co., Ltd., Nihon Kohden Corporation, Otsuka Pharmaceutical Co., and UCB Japan Co., Ltd. He also receives honorarium from Eisai Co., Ltd and UCB Japan Co., Lt

J. Helen Cross has acted as an investigator for studies with GW Pharma, Zogenix, Vitaflor and Marinus. She has been a speaker and on advisory boards for GW Pharma, Zogenix, and Nutricia; all remuneration has been paid to her department. Her research is supported by the National Institute of Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital. She holds an endowed chair at UCL Great Ormond Street Institute of Child Health; she holds grants from NIHR, EPSRC, GOSH Charity, ERUK, and the Waterloo Foundation

Jo Wilmshurst receives an honorarium for her role of associate editor for *Epilepsia*.

M Seeck received speaker's fees of EGI Philips, holds shares of Epilog and received consulting fees from the Wyss Foundation.

N. K. Focke received speaker bureaus and consultancy fees from Bial, Eisai and EGI/Phillips outside the submitted work.

Patricia Braga reports no conflicts of interest.

Samuel Wiebe, through his institution, has received unrestricted educational grants from UCB Pharma, Sunovion and Eisai.

Dr. Schuele has received personal compensation in form of a stipend from Wolters Kluwer as Associate Editor of the *Journal of Clinical Neurophysiology*. He receives royalties from a book published from Demos Publishers Inc., Springer Publishing on Stereo-encephalography. Honoraria for speaking engagements have been received from the American Academy of Neurology, American Epilepsy Society, American Clinical Neurophysiology Society, Sunovion Inc., SK Life Science, Neurelis, and Greenwich. Eugen Trinka reports personal fees from EVER Pharma, Marinus, Arvelle, Argenix, Medtronic, Bial-Portela & C<sup>a</sup>, NewBridge, GL Pharma, GlaxoSmithKline, Boehringer Ingelheim, LivaNova,

Eisai, UCB, Biogen, Genzyme Sanofi, and Actavis; his institution received grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF Österreichischer Fond zur Wissenschaftsförderung, Bundesministerium für Wissenschaft und Forschung, and Jubiläumsfond der Österreichischen Nationalbank outside the submitted work.

## References

1. Krysl D, Beniczky S, Franceschetti S, Arzimanoglou A. The COVID-19 outbreak and approaches to performing EEG in Europe. *Epileptic Disord* 2020; 22(5): 548-54.
2. Tatum WO, Rubboli G, Kaplan PW, Mirsafari SM, Radhakrishnan K, Gloss D, et al. Clinical utility of EEG in diagnosing and monitoring epilepsy in adults. *Clin Neurophysiol* 2018; 129(5): 1056-82.
3. Kobulashvili T, Kuchukhidze G, Brigo F, Zimmermann G, Höfler J, Leitinger M, et al. Diagnostic and prognostic value of noninvasive long-term video-electroencephalographic monitoring in epilepsy surgery: a systematic review and meta-analysis from the E-PILEPSY consortium. *Epilepsia* 2018; 59: 2272-83.
4. Uldall P, Alving J, Hansen LK, Kibaek M, Buchholt J. The misdiagnosis of epilepsy in children admitted to a tertiary epilepsy centre with paroxysmal events. *Arch Dis Child* 2006; 91: 219-21.
5. Asano E, Pawlak C, Shah A, Shah J, Luat AF, Ahn-Ewing J, et al. The diagnostic value of initial video-EEG monitoring in children - review of 1,000 cases. *Epilepsy Res* 2005; 66: 129-35.
6. McBride AE, Shih TT, Hirsch LJ. Video-EEG monitoring in the elderly: a review of 94 patients. *Epilepsia* 2002; 43: 165-9.
7. Chadwick D, Smith D. The misdiagnosis of epilepsy. *BMJ* 2002; 324: 495-6.
8. Ferrie CD. Preventing misdiagnosis of epilepsy. *Arch Dis Child* 2006; 91: 206-9.
9. LaFrance WC Jr, Benbadis SR. Avoiding the costs of unrecognized psychological nonepileptic seizures. *Neurology* 2006; 13(66): 1620-1.
10. Nightscales R, McCartney L, Auvrez C, Tao G, Barnard S, Malpas CB, et al. Mortality in patients with psychogenic nonepileptic seizures. *Neurology* 2020; 95(6): e643-52.
11. Wiebe S, Blume WT, Girvin JP, Eliasziw M. Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. *N Engl J Med* 2001; 345(5): 311-8.
12. Engel J Jr, McDermott MP, Wiebe S, Langfitt JT, Stern JM, Dewar S, et al. Early Randomized Surgical Epilepsy Trial (ERSET) Study Group. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. *JAMA* 2012; 307(9): 922-30.
13. Dwivedi R, Ramanujam B, Chandra PS, Sapra S, Gulati S, Kalaivani M, et al. Surgery for drug-resistant epilepsy in Children. *N Engl J Med* 2017; 377(17): 1639-47.

14. Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. *Lancet Neurol* 2016; 15(10): 1075-88.
15. Lowerison MW, Josephson CB, Jetté N, Sajobi TT, Patten S, Williamson T, et al. Association of levels of specialized care with risk of premature mortality in patients with epilepsy. *JAMA Neurol* 2019; 76(11): 1352-8.
16. Hargreaves DS, Arora S, Viveiro C, Hale DR, Ward JL, Sherlaw-Johnson C, et al. Association of quality of paediatric epilepsy care with mortality and unplanned hospital admissions among children and young people with epilepsy in England: a national longitudinal data linkage study. *Lancet Child Adolesc Health* 2019; 3: 627-35.
17. Granbichler CA, Oberaigner W, Kuchukhidze G, Ndayisaba JP, Ndayisaba A, Taylor A, et al. Decrease in mortality of adult epilepsy patients since 1980: lessons learned from a hospital-based cohort. *Eur J Neurol* 2017; 24: 667-72.
18. Joint proposals by the Japan Epilepsy Society, Japanese Society of Clinical Neurophysiology, The Japan Neurosurgical Society, Japanese Society of Neurology, Japanese Society of Child Neurology, and Japanese Society of Psychiatry and Neurology. *Alert for EEG examinations to prevent COVID-19 infection*. Available at: <https://www.ilae.org/files/dmfile/JES-Alert-for-EEG-examinations.pdf>. Latest accessed: February 6, 2020.
19. Gélisse P, Rossetti AO, Genton P, Crespel A, Kaplan PW. How to carry out and interpret EEG recordings in COVID-19 patients in ICU? *Clin Neurophysiol* 2020; 131: 2023-31.
20. San-Juan D, Jiménez CR, Camilli CX, de la Cruz Reyes LA, Galindo EGA, Burbano GER, et al. Guidance for clinical neurophysiology examination throughout the COVID-19 pandemic. Latin American chapter of the IFCN task force - COVID-19. *Clin Neurophysiol* 2020; 131: 1589-98.